NASDAQ · Drug Manufacturers - Specialty & Generic

Alvotech (ALVO) Stock

$3.16 +3.10% NASDAQ: ALVO Healthcare

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer.

Valuation

MetricValue
Price$3.16
Market Cap$1.07B
P/E Ratio-10.76
P/B Ratio-3.58
P/S Ratio1.85
EPS (TTM)$0.10
52-Week High$9.94
52-Week Low$2.94
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE35.22%
ROA-5.68%
ROCE6.65%
Gross Margin13.31%
Operating Margin13.31%
Net Margin-14.43%
Debt/Equity-5.16
Current Ratio1.89

Annual Financials (USD)

Metric20212022202320242025
Revenue$37.0M$83.0M$91.0M$490.0M$586.0M
Operating Profit$-235.0M$-346.0M$-355.0M$70.0M$78.0M
Net Profit$-102.0M$-514.0M$-552.0M$-232.0M$28.0M
EPS$-3.25$-2.60$-2.43$-0.87$0.10
Op Margin-640.3%-417.3%-388.1%14.2%13.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$598.0M$828.0M$950.0M$1.2B$1.5B
Total Liabilities$734.0M$1.4B$1.9B$1.6B$1.8B
Cash$18.0M$66.0M$11.0M$51.0M$172.0M
Borrowings$523.0M$805.0M$1.1B$1.2B$1.4B

Latest News

Alvotech Faces 'Soft' Q2 but Well Positioned to Benefit From Upcoming Biosimilar Opportunity, UBS Says MT Newswires · Jul 6, 2026 Transactions of Managers and Closely Associated Persons GlobeNewswire · Jul 3, 2026 Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering Simply Wall St. · Jul 2, 2026 Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO) Simply Wall St. · Jul 2, 2026 Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Fed Chair Warsh's International Debut MT Newswires · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-228.0M$-312.0M$-312.0M$-237.0M$-50.0M
Investing Cash Flow$-81.0M$-113.0M$-93.0M$-76.0M$-169.0M
Financing Cash Flow$0$157.0M$-7.0M$-5.0M$-10.0M
Net Cash Flow$-14.0M$49.0M$-55.0M$40.0M$121.0M
Free Cash Flow$-269.0M$-361.0M$-359.0M$-294.0M$-115.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.10
EV / EBITDA20.21
FCF Yield-10.78%
Quick Ratio1.16
Interest Coverage0.52
Return 1Y-65.28%
Return 3Y-68.42%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMPH $20.22 +1.40% 12.02 $891.56M 0.00%
BHVN $14.07 +3.19% -6.11 $2.12B 0.00%
COLL $35.58 +0.54% 17.33 $1.15B 0.00%
EVOEvotec SE $2.01 -6.07% -3.26 $713.93M 0.00%
HROW $39.09 +0.83% 14.50 $1.46B 0.00%

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Alvotech is led by CEO Lisa Graver, employs 1,012 people, headquartered in IS, publicly traded since 2022.

Alvotech (ALVO) stock trades at $3.16 with a market capitalization of $1.07B. The stock is valued at a price-to-earnings (P/E) ratio of -10.76, price-to-book of -3.58, price-to-sales of 1.85. Over the past 52 weeks the stock has ranged between $2.94 and $9.94, and currently trades 68.2% below its 52-week high.

On profitability, Alvotech generates a return on equity (ROE) of 35.22% — well above the market average, a sign of a high-quality business, return on capital employed of 6.65%, an operating margin of 13.31%, a net profit margin of -14.43%.

Official website: www.alvotech.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides